Ovarian cancer continues to be one of the most challenging gynecological tumors in Argentina and worldwide. Each year, approximately 2,200 cases are diagnosed in the country, and about 70% of patients are already in advanced stages at the time of consultation, when the disease has already spread beyond the ovary, significantly reducing the chances of a cure.
The lack of effective screening methods for asymptomatic women, combined with the fact that initial symptoms are often vague or nonspecific—such as persistent abdominal bloating, digestive discomfort, pelvic pain, or a feeling of early fullness—contributes to delayed diagnosis.
Recently, a significant breakthrough has marked a paradigm shift: the arrival of a new therapeutic tool with a novel mechanism of action for this type of cancer. It is indicated for advanced cases resistant to platinum-based chemotherapy. Unlike conventional chemotherapy, which acts systemically and non-specifically, this strategy allows for targeting the therapeutic action on tumors that express certain biomarkers.
«Today, testing the molecular profile of cancer has become indispensable, as it allows us to identify which patients can benefit from these personalized therapies and thus make more precise decisions and optimize clinical outcomes,» explained a doctor.
Experts emphasize that equity in the availability of molecular diagnostics, access to cutting-edge treatments, and care in specialized centers remains a challenge to ensure all patients have the same therapeutic opportunities.
Beyond oncological treatment, the management of ovarian cancer requires a comprehensive approach that includes nutritional support, psychological support, social accompaniment, and, when appropriate, palliative care to improve quality of life.
Recent international clinical studies have demonstrated that this new approach improves survival and disease control compared to traditional regimens used so far in patients with platinum-resistant ovarian cancer. The current scenario opens an era of greater hope for a disease historically sidelined in terms of innovation.
